OCEAW
Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The company is developing mono-specific and bi-specific humanized monoclonal antibodies (mAb) product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. It is also developing three product candidates based on the WPDS platform, including a malaria vaccine candidate; a humanized mAb malaria therapeutic candidate targeting Plasmodium falciparum glutamic-acid-rich protein (PfGARP); and a small molecule malaria therapeutic candidate targeting PfGARP, as well as a product candidate for the treatment of COVID-19 in hospitalized patients. The company was incorporated in 2019 and is based in Providence, Rhode Island.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q1 | -0.30 | $0 | -$356,000 |
| 2024 Q4 | 0.01 | $0 | -$3M |
| 2024 Q3 | -0.20 | $0 | -$885,000 |
| 2024 Q2 | -0.63 | $0 | -$290,000 |
| 2024 Q1 | 0.48 | $0 | -$485,000 |
| 2023 Q4 | -0.62 | $0 | -$866,000 |
| 2023 Q3 | -0.53 | $0 | -$1M |
| 2023 Q2 | -0.49 | $0 | -$5M |